Direct comparisons of these two phenotypically distinct Th9 cells suggests that Th9IL-4+IL-1β cells display higher tumor-specific cytotoxicity in vitro and improved tumor clearance in vivo compared to classic Th9IL-4+TGF-β cells. The gene discussed is IL1B; the disease is neoplasm.